FindTrial
Sign In

Ablation with Low-Dose (1.1GBq) and High-Dose (3.7GBq) Radioiodine in Postoperative Low-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Open-label, Controlled Clinical Study

Ablation with Low-Dose (1.1GBq) and High-Dose (3.7GBq) Radioiodine in Postoperative Low-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Open-label, Controlled Clinical Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-15006139
Enrollment
Unknown
Registered
2014-08-12
Start date
2014-09-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid Cancer

Interventions

1:30mCi
2:100mCi

Sponsors

West China hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Aged over 18, low-risk differentiated thyroid cancer, including papillary thyroid cancer and follicular thyroid cancer, T1N0~1M0, T2N0M0, after total thyroidectomy and appropriate extent of neck lymph node dissection, receiving 131I therapy for the first time, patients agree to participate in the clinical trial.

Exclusion criteria

Exclusion criteria: The tumor does not have aggressive histology (e.g., tall cell, insular, columnar cell carcinoma, poorly differentiated carcinoma, diffuse sclerosing variant, anaplastic thyroid carcinoma,medullary thyroid cancer). The patients who suffered from other tumor.

Design outcomes

Primary

MeasureTime frame
thyroglobulin;Diagnostic radioiodine scan;Radioactive sialadenitis;Radioactive gastritis;absence of remnant tissue and abnormal lymph nodes on neck Ultrasound;—

Contacts

Public ContactLi Lin
lillinhuaxi@sina.com+86 18980601584

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 12, 2026